TRXC - TransEnterix, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
4.57
+0.13 (+2.93%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.44
Open4.44
Bid0.00 x 900
Ask0.00 x 1800
Day's Range4.44 - 4.71
52 Week Range0.72 - 6.04
Volume3,037,360
Avg. Volume7,590,053
Market Cap954.988M
Beta2.46
PE Ratio (TTM)N/A
EPS (TTM)-0.80
Earnings DateNov 7, 2017 - Nov 13, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.17
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents21 hours ago

    Edited Transcript of TRXC earnings conference call or presentation 7-Aug-18 12:30pm GMT

    Q2 2018 Transenterix Inc Earnings Call

  • Inside The List: Breakdown of size, location of NC's publicly traded companies
    American City Business Journalsyesterday

    Inside The List: Breakdown of size, location of NC's publicly traded companies

    In its latest look at the financials of these publicly traded companies, Triangle Business Journal dove deeper into the data to see how these companies fall in the various regions of the state and how those areas stack up as of July 31, 2018 – and how these companies compare to last year.

  • Why TransEnterix Stock Rocketed Higher in July
    Motley Fool7 days ago

    Why TransEnterix Stock Rocketed Higher in July

    Shares of this tiny robotic-surgery company benefited from a positive corporate update last month.

  • Some highs, lows as RTP biotech companies report earnings
    American City Business Journals8 days ago

    Some highs, lows as RTP biotech companies report earnings

    Earnings season is in full swing, and companies are busy reporting their performance for the second quarter of the fiscal year.   The same is true for Research Triangle Park’s biotech companies, BioDelivery Sciences (Nasdaq: BDSI), TransEnterix (Amex: TRXC) and Dova Pharmaceuticals (Nasdaq: DOVA) all announced their financial results during after-market hours in recent days.

  • Why TransEnterix Shares Dropped 11.7% Today
    Motley Fool11 days ago

    Why TransEnterix Shares Dropped 11.7% Today

    An increase in robotic surgery system sales failed to offset concerns over the company's net loss.

  • An Overview of TransEnterix’s Q2 2018 Results
    Market Realist11 days ago

    An Overview of TransEnterix’s Q2 2018 Results

    TransEnterix (TRXC) reported its second-quarter earnings on Tuesday, August 7, before the market opened. TransEnterix generated second-quarter revenues of $6.4 million compared to $1.6 million in the second quarter of 2017. 

  • TransEnterix sees revenue climb on surgical robot sales
    American City Business Journals11 days ago

    TransEnterix sees revenue climb on surgical robot sales

    TransEnterix (NYSE: TRXC) is seeing its revenue climb on more sales following its initial U.S. Food and Drug Administration clearance late last year, although the company is still showing losses overall. On Tuesday, the Research Triangle Park-based surgical robot maker reported revenue of $6.4 million in the second quarter of 2018, compared to revenue of just $1.6 million in the second quarter of last year. TransEnterix reported a net loss of $34.2 million, or $0.17 per share, for the second quarter of 2018, compared to a net loss of $14.7 million, or $0.11 per share, for the second quarter of last year.

  • TransEnterix (TRXC) Reports Q2 Loss, Tops Revenue Estimates
    Zacks11 days ago

    TransEnterix (TRXC) Reports Q2 Loss, Tops Revenue Estimates

    TransEnterix (TRXC) delivered earnings and revenue surprises of 0.00% and 3.05%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press11 days ago

    TransEnterix: 2Q Earnings Snapshot

    The Morrisville, North Carolina-based company said it had a loss of 17 cents per share. Losses, adjusted for non-recurring costs and amortization costs, were 6 cents per share. The maker of surgical robots ...

  • Business Wire11 days ago

    TransEnterix, Inc. Reports Operating and Financial Results for the Second Quarter 2018

    TransEnterix, Inc. , a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced its operating and financial results for the second quarter 2018.

  • ACCESSWIRE11 days ago

    TransEnterix, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 7, 2018 / TransEnterix, Inc. (NYSE American: TRXC ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 8:30:00 AM Eastern ...

  • Business Wire25 days ago

    TransEnterix Schedules Second Quarter 2018 Financial and Operating Results Conference Call for August 7, 2018

    TransEnterix, Inc. announced today that it plans to release second quarter 2018 financial and operating results before the market opens on Tuesday, August 7, 2018.

  • Senhance Expected to Boost TransEnterix’s Revenue beyond 2018
    Market Realistlast month

    Senhance Expected to Boost TransEnterix’s Revenue beyond 2018

    In June, TransEnterix (TRXC) submitted its 510(k) filing to the FDA for approval of additional Senhance system instruments. In the United States, Senhance has been approved by the FDA for laparoscopic gynecology, colorectal, inguinal hernia, and cholecystectomy surgical procedures. In May, the FDA cleared TransEnterix’s 510(k) for expansion of the use of Senhance for laparoscopic inguinal hernia and cholecystectomy surgery.

  • How TransEnterix Is Positioned Financially
    Market Realistlast month

    How TransEnterix Is Positioned Financially

    In the first quarter, TransEnterix (TRXC) generated revenues of $4.8 million compared to $1.9 million in Q1 2017, reflecting a 145% year-over-year growth. It reported cost of revenue of $2.6 million compared to $1.3 million in the first quarter of 2017. Wall Street analysts estimate that TransEnterix will generate revenues of $5.66 million in the second quarter. On July 2, in TransEnterix’s corporate update, it noted that its second-quarter revenues would be $6 million–$6.3 million.

  • How Wall Street Analysts View TransEnterix
    Market Realistlast month

    How Wall Street Analysts View TransEnterix

    On July 12, TransEnterix (TRXC) stock closed at $4.44, reflecting a 2.78% growth from its prior day’s close of $4.32. On July 11, the stock rose 8.54% from its close of $3.98 on July 10. TransEnterix is focused on the development of medical devices that use robotics to improve minimally invasive surgery. On June 25, TransEnterix announced its addition to the Russell 2000 Index, effective June 25. Russell US indexes are used extensively by investors, institutional investors, and investment managers to create a benchmark for making investment strategies.

  • Investopedialast month

    Is Now a Good Time to Play the Biotech Sector With TransEnterix?

    TransEnterix Inc (NYSE: TRXC), a robotic medical device company aiming to digitize the interface between surgeons and patients in laparoscopy, surged an impressive 125.9% in the first half of 2018, owing to a multitude of bullish factors. The company seeks to assist qualified laparoscopists to perform complex surgeries with the assistance of robotic technology. Here we use TipRanks data to take a closer look at what Wall Street's top analysts see in store for this volatile stock.

  • ACCESSWIRElast month

    Free Stock Performance Review on TransEnterix and Three Additional Medical Supplies Stocks

    LONDON, UK / ACCESSWIRE / July 12, 2018 / If you want a free Stock Review on TRXC sign up now at www.wallstequities.com/registration. WallStEquities.com takes a close look at four Medical Instruments and Supplies stocks, particularly, Tandem Diabetes Care Inc. (NASDAQ: TNDM), The Cooper Cos. Inc. (NYSE: COO), TransEnterix Inc. (NYSE American: TRXC), and Waters Corp. (NYSE: WAT).

  • The Triangle's top inside stock sales in the first half of 2018
    American City Business Journalslast month

    The Triangle's top inside stock sales in the first half of 2018

    From Iqvia to Red Hat, insiders at Triangle companies have raked in millions in the first half of 2018 by selling shares, SEC filings show.

  • Here's Why TransEnterix Stock Spiked 125.9% in the First Half of 2018
    Motley Foollast month

    Here's Why TransEnterix Stock Spiked 125.9% in the First Half of 2018

    Good news from Senhance's commercial rollout keeps pushing up the robotic-surgery stock.

  • Business Wire2 months ago

    TransEnterix Provides Corporate Update

    TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between surgeons and patients to improve minimally invasive surgery, today provided a corporate update, including the announcement of the sale of an additional Senhance system as well as preliminary unaudited revenue for the second quarter ended June 30, 2018.

  • Implied Volatility Surging for TransEnterix (TRXC) Stock Options
    Zacks2 months ago

    Implied Volatility Surging for TransEnterix (TRXC) Stock Options

    TransEnterix (TRXC) needs investors to pay close attention to the stock based on moves in the options market lately.

  • Why Did TransEnterix Stock Fall on June 28?
    Market Realist2 months ago

    Why Did TransEnterix Stock Fall on June 28?

    On May 29, the FDA approved TransEnterix’s Senhance Surgical System in laparoscopic inguinal hernia and laparoscopic gallbladder removal indications. The sudden drop in TransEnterix’s share price is due to BTIG analyst Sean Lavin downgrading the stock to “neutral.” Also, the company withdrew its previous target price, which impacted overall investor sentiment.

  • Benzinga2 months ago

    BTIG Turns Neutral On TransEnterix, Says Stock Rally Unsupported By Fundamentals

    Transenterix Inc (NYSE: TRXC) shares have spiked 50 percent in the last week, 71 percent in the last month and 734 percent in the last year. By Lavin’s assessment, the pop in price reflects no fundamental improvements or risk alleviation around commercialization.

  • TransEnterix: Is It Time to Take Profits From This High-Flyer?
    Motley Fool2 months ago

    TransEnterix: Is It Time to Take Profits From This High-Flyer?

    An analyst downgrade crushed TransEnterix's shares this morning.

  • TransEnterix (TRXC) in Focus: Stock Moves 7% Higher
    Zacks2 months ago

    TransEnterix (TRXC) in Focus: Stock Moves 7% Higher

    TransEnterix (TRXC) was a big mover last session, as the company saw its shares rise nearly 7% on the day amid huge volumes.